It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The ability of transcription factors to discriminate between different classes of binding sites associated with specific biological functions underpins effective gene regulation in development and homeostasis. How this is achieved is poorly understood. The microphthalmia-associated transcription factor MITF is a lineage-survival oncogene that plays a crucial role in melanocyte development and melanoma. MITF suppresses invasion, reprograms metabolism and promotes both proliferation and differentiation. How MITF distinguishes between differentiation and proliferation-associated targets is unknown. Here we show that compared to many transcription factors MITF exhibits a very long residence time which is reduced by p300/CBP-mediated MITF acetylation at K206. While K206 acetylation also decreases genome-wide MITF DNA-binding affinity, it preferentially directs DNA binding away from differentiation-associated CATGTG motifs toward CACGTG elements. The results reveal an acetylation-mediated switch that suppresses differentiation and provides a mechanistic explanation of why a human K206Q MITF mutation is associated with Waardenburg syndrome.
The microphthalmia-associated transcription factor MITF is a lineage-survival oncogene that plays a crucial role in melanocyte development and melanoma. Here, the authors reveal that MITF has a very long chromatin-bound half-life, and that MITF target selectivity is regulated by K206 acetylation, a residue linked to Waardenburg syndrome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Oxford, Headington, Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Tsukuba, Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, Ibaraki, Japan (GRID:grid.20515.33) (ISNI:0000 0001 2369 4728)
2 Ospedale San Raffaele, Experimental Imaging Center, Milano, Italy (GRID:grid.18887.3e) (ISNI:0000 0004 1758 1884)
3 European Molecular Biology Laboratory, Hamburg Unit, Hamburg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X); University Hamburg Medical Centre Hamburg-Eppendorf, Institute of Biochemistry and Signal Transduction, Hamburg, Germany (GRID:grid.9026.d) (ISNI:0000 0001 2287 2617)
4 University of Oxford, Headington, Structural Genomics Consortium, Nuffield Department of Clinical Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 University of Oxford, Headington, Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Iceland, Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, Reykjavik, Iceland (GRID:grid.14013.37) (ISNI:0000 0004 0640 0021)
6 University of Oxford, Headington, Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
7 MRC Human Genetics Unit & Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK (GRID:grid.415854.9) (ISNI:0000 0004 0605 7892)
8 CHU de Québec – Université Laval Research Center, Department of Molecular Medicine and Cancer Research Center, Université Laval, Quebec, Canada; Endocrinology – Nephrology Axis, Quebec City, Canada (GRID:grid.411081.d) (ISNI:0000 0000 9471 1794)
9 University of Oxford, Central Proteomics Facility, Sir William Dunn Pathology School, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
10 European Molecular Biology Laboratory, Hamburg Unit, Hamburg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X); University Hamburg Medical Centre Hamburg-Eppendorf, Hamburg, Germany (GRID:grid.9026.d) (ISNI:0000 0001 2287 2617)
11 University of Iceland, Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, Reykjavik, Iceland (GRID:grid.14013.37) (ISNI:0000 0004 0640 0021)
12 Ospedale San Raffaele, Experimental Imaging Center, Milano, Italy (GRID:grid.18887.3e) (ISNI:0000 0004 1758 1884); Università Vita-Salulte San Raffaele, Milano, Italy (GRID:grid.15496.3f) (ISNI:0000 0001 0439 0892)